MiMedx Group Executive and Leadership Team

Joseph Capper, the Chief Executive Officer at MiMedx Group, directs the overarching corporate strategy and market positioning for the company's regenerative biologics. Overseeing the development and commercialization of patent-protected processes, Capper ensures MiMedx Group's offerings effectively address needs across wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. This leadership role involves guiding the executive team to drive innovation and expand the application of human placental tissue allografts. By fostering strategic partnerships and ensuring operational alignment, Joseph Capper significantly impacts the company's growth trajectory and its ability to deliver advanced healing solutions. The Chief Executive Officer's vision shapes the company's commitment to improving patient care through cutting-edge biomaterial technologies.

Douglas Rice, the Chief Financial Officer at MiMedx Group, manages all financial operations and fiscal strategy for the biopharmaceutical company. Rice oversees budgeting, forecasting, and financial reporting, ensuring robust fiscal health and compliance across the organization. This critical role involves managing capital allocation to support research and development of regenerative biologics, including those utilizing the proprietary PURION Process. By optimizing financial performance and securing investment, Douglas Rice directly contributes to the company's ability to scale its operations and expand its market reach internationally. The Chief Financial Officer's expertise is essential for sustaining the company's growth and its mission to provide advanced healing solutions.

William Taylor, the President & Chief Operating Officer & Board Member at MiMedx Group, drives the operational execution and day-to-day management of the company's business functions. Taylor oversees the manufacturing and distribution of regenerative biologics, ensuring the efficient application of patent-protected processes like the PURION Process. This leadership position involves coordinating the sales force, independent distributors, and third-party representatives to maximize market penetration across the United States and internationally. By enhancing operational efficiency and supply chain management, William Taylor ensures the consistent delivery of high-quality allografts for wound care, orthopedics, and other medical applications. The President & Chief Operating Officer & Board Member's focus on operational excellence underpins the company's commitment to patient outcomes.

David Mason, the Chief Medical Officer at MiMedx Group, leads the clinical strategy and medical affairs for the company's regenerative biologics. Mason oversees the clinical development and validation of products derived from human placental tissue, including AmnioFix, EpiFix, and EpiCord, ensuring their efficacy and safety across various medical disciplines. This role involves guiding research initiatives and fostering relationships with the medical community to advance the understanding and application of biomaterial platform technologies. By ensuring clinical integrity and driving evidence-based adoption, David Mason directly supports the company's mission to improve patient healing and recovery. The Chief Medical Officer's medical expertise is fundamental to MiMedx Group's innovation in regenerative medicine.

William Hulse, the General Counsel & Chief Administrative Officer at MiMedx Group, manages all legal affairs and oversees key administrative functions for the biopharmaceutical company. Hulse ensures compliance with regulatory requirements governing the development and marketing of regenerative biologics, including those processed using proprietary methods. This comprehensive role involves advising the executive team on legal matters, managing corporate governance, and overseeing administrative operations to support the company's strategic objectives. By safeguarding the company's legal interests and streamlining administrative processes, William Hulse contributes to operational stability and facilitates the company's expansion into new markets. The General Counsel & Chief Administrative Officer's diligence is vital for maintaining trust and integrity.